Binifibrate is a fibrate drug used to lower cholesterol levels. It is a synthetic compound that acts as an agonist of peroxisome proliferator-activated receptor alpha (PPARα). PPARα is a nuclear receptor that plays a role in lipid metabolism and the regulation of cholesterol levels. Binifibrate is studied for its potential benefits in treating hyperlipidemia, a condition characterized by high levels of cholesterol in the blood. It is also being investigated for its potential role in preventing cardiovascular disease. Binifibrate is synthesized through a multi-step process involving various chemical reactions. The specific synthesis route is complex and involves several intermediates. It is important to note that the information provided here is for general knowledge purposes only and should not be construed as medical advice.'
binifibrate: two nicotinic & one clofibiric radical esterified by glycerol moiety [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68884 |
| CHEMBL ID | 2106582 |
| CHEBI ID | 135800 |
| SCHEMBL ID | 49116 |
| MeSH ID | M0116778 |
| Synonym |
|---|
| wac-104 |
| binifibrate |
| biniwas |
| binifibrato |
| antopal retard |
| wac 104 |
| 2-(p-chlorophenoxy)-2-methylpropionic acid ester with 1,3-dinicotininoyloxy-2-propanol |
| binifibrato [inn-spanish] |
| glyceryl 2-p-chlorophenoxyisobutyrate-1,3-dinicotinate |
| binifibratum [inn-latin] |
| 3-pyridinecarboxylic acid, 2-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)-1,3-propanediyl ester |
| trihydroxypropane 2-p-chlorophenoxyisobutyrate-1,3-dinicotinate |
| binifibrate [inn] |
| 69047-39-8 |
| biniwas (tn) |
| D07529 |
| binifibrate (inn) |
| CHEBI:135800 |
| [2-[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy-3-(pyridine-3-carbonyloxy)propyl] pyridine-3-carboxylate |
| binifibratum |
| 9ngz4gpe20 , |
| unii-9ngz4gpe20 |
| CHEMBL2106582 |
| binifibrate [mart.] |
| binifibrate [mi] |
| binifibrate [who-dd] |
| 3-pyridinecarboxylicacid, 3,3'-[2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]-1,3-propanediyl]ester |
| SCHEMBL49116 |
| DTXSID80219113 |
| Q12200764 |
| CS-0066932 |
| HY-116977 |
| AKOS040747983 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The treatment with binifibrate was applied at a dosage of 3 X 600 mg/day during one month." | ( Microhaemorheological properties of binifibrate. Part II: Preliminary open studies in patients with peripheral arteriopathies. Andreoli, R; Bruseghini, L; Dalmau, M; Diez, S; Freixes, J; Monasterio, J; Nogués, R; Picó, M, 1983) | 0.86 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The treatment with binifibrate was applied at a dosage of 3 X 600 mg/day during one month." | ( Microhaemorheological properties of binifibrate. Part II: Preliminary open studies in patients with peripheral arteriopathies. Andreoli, R; Bruseghini, L; Dalmau, M; Diez, S; Freixes, J; Monasterio, J; Nogués, R; Picó, M, 1983) | 0.86 |
| Class | Description |
|---|---|
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||